Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. (19th December 2020)

• Record Type: Journal Article
• Authors: Harrison, Douglas J.; Chi, Yueh‐Yun; Tian, Jing; Hingorani, Pooja; Mascarenhas, Leo; McCowage, Geoffrey B.; Weigel, Brenda J.; Venkatramani, Rajkumar; Wolden, Suzanne L.; Yock, Torunn I.; Rodeberg, David A.; Hayes‐Jordan, Andrea A.; Teot, Lisa A.; Spunt, Sheri L.; Meyer, William H.; Hawkins, Douglas S.; Shulkin, Barry L.; Parisi, Marguerite T.
• Is Part Of: Cancer medicine. Volume 10:Number 3(2021)
• Page Start: 857
• Page End: 866
• Publication Date: 2020-12-19
• Subjects: chemotherapy -- complete metabolic response -- maximum standard uptake value (SUVmax) -- pediatric -- positron emission tomography -- rhabdomyosarcoma; 616.994005
• DOI: 10.1002/cam4.3667
• Languages: English
• ISSNs: 2045-7634

Abstract

ABSTRACT: Background: Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification to assign therapy aiming to minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18 F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG‐PET) imaging and event‐free survival (EFS) in intermediate‐risk (IR) and high‐risk (HR) RMS patients. Methods: FDG‐PET imaging characteristics, including assessment of CMR and maximum standard uptake values (SUVmax) of the primary tumor, were evaluated by central review. Institutional reports of SUVmax were used when SUVmax values could not be determined by central review. One hundred and thirty IR and 105 HR patients had FDG‐PET scans submitted for central review or had SUVmax data available from institutional report at any time point. A Cox proportional hazards regression model was used to evaluate the relationship between these parameters and EFS. Results: SUVmax at study entry did not correlate with EFS for IR ( p = 0.32) or HR ( p = 0.86) patients. Compared to patients who did not achieve a CMR, EFS was not superior for IR patients who achieved a CMR at weeks 4 ( p = 0.66) or 15 ( p = 0.46), nor for HR patients who achieved CMR at week 6 ( p = 0.75) or 19 ( p = 0.28). Change in SUVmax at week 4 ( p = 0.21) or 15 ( p = 0.91) for IR patients or at week 6 ( p = 0.75) or 19 ( p = 0.61) for HR patients did not correlate with EFS. Conclusion: Based on these data, FDG‐PET does not appear to predict EFS in IR or HR‐RMS. It remains to be determined whether FDG‐PET has a role in predicting survival outcomes in other RMS subpopulations. Abstract : This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18 F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG‐PET) imaging and event‐free survival (EFS) in intermediate‐risk (IR) and high‐risk (HR) RMS patients. FDG‐PET parameters including baseline SUVmax, change in SUVmax, and CMR do not predict EFS in IR or HR‐RMS.